Work

Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group

Year: 2017
Type: review
Abstract: The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest challenges for achieving malaria elimination from the Asia-Pacific by 2030. During the annual meeting of the Asia Pacific Malaria Elimination Network Vivax Working Group in October 2016, a round table discussion was held to discuss the programmatic issues hindering the widespread use of primaquine (PQ) radical cure. Participants included 73 representatives from 16 partner countries and 33 institutional partners and other research institutes. In this meeting report, the key discussion points are presented and grouped into five themes: (i) current barriers for glucose-6-phosphate deficiency (G6PD) testing prior to PQ radical cure, (ii) necessary properties of G6PD tests for wide scale deployment, (iii) the promotion of G6PD testing, (iv) improving adherence to PQ regimens and (v) the challenges for future tafenoquine (TQ) roll out. Robust point of care (PoC) G6PD tests are needed, which are suitable and cost-effective for clinical settings with limited infrastructure. An affordable and competitive test price is needed, accompanied by sustainable funding for the product with appropriate training of healthcare staff, and robust quality control and assurance processes. In the absence of quantitative PoC G6PD tests, G6PD status can be gauged with qualitative diagnostics, however none of the available tests is currently sensitive enough to guide TQ treatment. TQ introduction will require overcoming additional challenges including the management of severely and intermediately G6PD deficient individuals. Robust strategies are needed to ensure that effective treatment practices can be deployed widely, and these should ensure that the caveats are outweighed by the benefits of radical cure for both the patients and the community. Widespread access to quality controlled G6PD testing will be critical.
Institutions: Charles Darwin University, Menzies School of Health Research, Cambodia National Malaria Center, National Institute of Public Health, International Centre for Diarrhoeal Disease Research, Universitas Sumatera Utara, Mahidol University, Medicines for Malaria Venture, Program for Appropriate Technology in Health, University of Oxford, Mahidol Oxford Tropical Medicine Research Unit, Directorate General of Health Services, Ministry of Health and Family Welfare, Ministry of Health, Ministry of Health and Family Welfare, Ministry of Health, Government of Nepal, Ministry of Health and Population, Department of Health Services, Department of Health, Korea Disease Control and Prevention Agency, Korea Center for Disease Control and Prevention, Ministry of Public Health, Department of Disease Control, National Institute of Malariology, Parasitology and Entomology, Australian Defence Force Malaria and Infectious Disease Institute, Burnet Institute, Kementerian Kesehatan Republik Indonesia, Eijkman Institute for Molecular Biology, FIND, Jiangsu Institute of Parasitic Diseases, Karolinska Institutet, Osaka City University, Centre for Human Genetics, Wellcome Sanger Institute, Malaria Consortium, Indian Council of Medical Research, Research Institute for Tropical Medicine, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, United States Agency for International Development, U.S. President's Malaria Initiative, World Health Organization, World Health Organization Regional Office for the Western Pacific, World Health Organization - Philippines, University of Washington, QIMR Berghofer Medical Research Institute, Oxford University Clinical Research Unit Indonesia
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,869
OpenAlex ID: W2604837458
FWCI: 1.332
Cites: 49
Cited by: 83
Related to: 10